In basal-like breast cancer, tumor cell populations, which persist following treatment with the MEK inhibitor, Trametinib, and the PI3K/mTOR inhibitor, BEZ235, showed increased activity of BRD4, KDM5B and EZH2 [78]. Here, PIK3CA is linked to breast carcinoma.